The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1295
September 22, 2008
View Complete Issue         Table of Contents 2019 
Ciclesonide (Alvesco) - A New Inhaled Corticosteroid for Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ciclesonide (Alvesco) - A New Inhaled Corticosteroid for Asthma
September 22, 2008 (Issue: 1295)
The FDA has approved the marketing of the corticosteroid ciclesonide (Alvesco - Sepracor) in a hydrofluoroalkane (HFA) metered-dose inhaler formulation for maintenance treatment of asthma in patients >12 years old. Ciclesonide is also available in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ciclesonide (Alvesco) - A New Inhaled Corticosteroid for Asthma
Article code: 1295b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.